MedTrace Logo

Efficacy and Safety of Different Doses of Rituximab Therapy in Pemphigus Patients

NCT07457944 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 275

Last updated 2026-03-09

No results posted yet for this study

Summary

Investigating the clinical efficacy of different doses of rituximab in patients with pemphigus

Conditions

  • Pemphigus Disease
  • Rituximab (RTx)

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Guangdong Provincial Dermatology Hospital

    collaborator OTHER_GOV

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Second Xiangya Hospital of Central South University

    collaborator OTHER

  • Ruijin Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2023-01-01
Completion
2026-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07457944 on ClinicalTrials.gov